Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.
äŒæ¥ã³ãŒãANIX
äŒç€ŸåAnixa Biosciences Inc
äžå Žæ¥Oct 07, 1983
æé«çµå¶è²¬ä»»è
ãCEOãKumar (Amit)
åŸæ¥å¡æ°5
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Oct 07
æ¬ç€Ÿæåšå°3150 Almaden Expy Ste 250
éœåžSAN JOSE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·95118
é»è©±çªå·14087089808
ãŠã§ããµã€ãhttps://www.anixa.com/
äŒæ¥ã³ãŒãANIX
äžå Žæ¥Oct 07, 1983
æé«çµå¶è²¬ä»»è
ãCEOãKumar (Amit)